On September 23, 2024, Orgenesis Inc.(Nasdaq: ORGS), a biotechnology company specializing in cell and gene therapies, announced a strategic move to enhance its stock performance by implementing a 1-for-10 reverse stock split, effective at 5:00 PM Eastern Time on September 24, 2024.This corporate action is aimed at consolidating the number of shares outstanding and increasing the per-share trading price, which can help boost the company’s profile in the capital markets.
Following the split, Orgenesis’ common stock will continue to be traded on The Nasdaq Capital Market under its existing symbol ORGS, commencing on September 25, 2024, with adjusted pricing reflecting the split.Prior to the split, Orgenesis had approximately 33.18 million shares outstanding and was trading at $0.5174 per share.Thus, post-split, the existing share price should theoretically rise to around $5.17, although actual market performance can vary based on investor sentiment and broader market conditions.
This reverse stock split comes at a pivotal time for Orgenesis, particularly following the recent announcement on August 29, 2024, regarding a significant breakthrough in the company’s pipeline.The firm revealed that its ORG-101 CAR-T therapy achieved a landmark success in treating CD19+ Acute Lymphoblastic Leukemia.This development marks a critical advancement for the company, showcasing its potential in the lucrative CAR-T therapy market.
Success in the clinical trials for ORG-101 has the potential to enhance investor confidence and draw greater attention from institutional investors, especially considering the competitive landscape of targeted cancer therapies.A higher stock price may also help Orgenesis avoid delisting from Nasdaq, where companies are required to maintain minimum trading prices.
Orgenesis’ strategic decisions, including the reverse stock split and its ongoing innovations in cellular therapy, seem to be aimed at strengthening its position not only in the stock market but also within the biopharmaceutical industry at large.As the company navigates these transformative changes, stakeholders will be keenly observing the market’s reaction, particularly in light of its promising developments in cancer treatment.
In summary, Orgenesis Inc.is maneuvering through a crucial phase of corporate restructuring and promising clinical advancements.By increasing its stock price through a reverse split and simultaneously fostering groundbreaking research, the company is positioning itself to enhance shareholder value and advance its mission in the biotechnology arena.
Comments